Coldamaris lozenges are a medical device containing 10 mg carrageenan/lozenge. The goal of the study is to determine whether the iota-carrageenan content in the saliva of subjects who sucked Coldamaris® lozenges is sufficient to inhibit the replication of 4 of the most common respiratory viruses causing common cold. At least 29 subjects will be screened, in order to get 24 subjects included.
Coldamaris lozenges are a medical device containing 10 mg carrageenan/lozenge. The goal of
the study is to determine whether the iota-carrageenan content in the saliva of subjects who
sucked Coldamaris® lozenges is sufficient to inhibit the replication of 4 of the most common
respiratory viruses causing common cold. At least 29 subjects will be screened, in order to
get 24 subjects included.
The primary objective is whether the mean iota-carrageenan concentration in saliva during
sucking an iota-carrageenan containing lozenge reaches published IC90 values for HRV1a and
HRV8.
The secondary objectives are whether the mean iota-carrageenan concentration in saliva
(µg/ml; base line corrected) during sucking an iota-carrageenan containing lozenge reaches
the respective IC90/MIC values (paired t-tests) of the clinical saliva samples for HRV1a,
HRV8, hCoV OC43, influenza virus H1N1n and Coxsackie virus A10.
Device: Coldamaris lozenges
sucking carageenan containing lozenge
Other Name: Array
Inclusion Criteria:
- personally signed and dated informed consent
- healthy respiratory tract, no acute infection
- age > 18 years
Exclusion Criteria:
- subjects with signs of an acute respiratory infection
- subjects with a known hypersensitivity to one of the ingredients
- presence of pregnancy confirmed
Dr. Friedrich Ehrenreich
Vienna, Austria